Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain wave clues: could inflammation markers forecast ECT outcomes?

NCT ID NCT07748091

Knowledge-focused Sponsor: Istanbul University - Cerrahpasa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study looks at whether brain wave patterns and inflammation markers in the blood can help predict how well electroconvulsive therapy (ECT) works for people with severe depression that hasn't improved with medication. Researchers will measure these markers before and after ECT in about 62 participants, including a healthy control group. The goal is to understand the brain changes linked to ECT and potentially guide more personalized depression treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electroconvulsive therapy (ECT) using the Thymatron System IV device
What this could lead to
If successful, this could help doctors predict which patients with treatment-resistant depression will respond to ECT, and could pave the way for more personalized treatment approaches.
What could go wrong
This is an early-stage, observational study with a small number of participants. It aims to find patterns, not prove a treatment works, and the results may not apply to all patients. ECT itself carries risks like memory problems and confusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients between 18 and 60 years of age diagnosed with Treatment-Resistant Major Depressive Disorder and suggested ECT sessions.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient Group * Age 18-60 years * Diagnosis of Major Depressive Disorder, current major depressive episode, according to DSM-5 criteria. * Clinical indication for electroconvulsive therapy (ECT). * Ability to provide written informed consent. * Willingness to participate in the study. Healthy Control Group: * Age ≥55 years. * No current psychiatric disorder. * No known neurological disorder. * Good general physical health. * No current use of medications known to affect EEG activity or inflammatory biomarkers significantly. * Ability to provide written informed consent. * Willingness to participate in the study. Exclusion Criteria: * Primary neurological disorders (e.g., dementia or traumatic brain injury). * Schizophrenia or other psychotic disorders. * Bipolar disorder diagnosis, * Intracranial space-occupying lesions. * Increased intracranial pressure. * Myocardial infarction within the previous 3 months. * Cerebrovascular disease within the previous month. * Unstable cerebral aneurysm. * Pheochromocytoma. * Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month. * Cognitive impairment severe enough to prevent adequate cooperation during EEG recording. * Current alcohol or substance use disorder. * Active infectious disease. * Autoimmune or chronic inflammatory disorders. * Current use of systemic corticosteroids, immunosuppressive agents, or other medications known to affect inflammatory biomarkers significantly.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depression Major depression moderate Major depression severe Major depression with comorbid anxiety symptoms Major depression with panic attacks Major depression with psychotic features Major depressive disorder (MDD) Major depressive episode

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department

    RECRUITING

    Istanbul, Bakırköy, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.